TICKERNERD
Menu
LUNGLUNGHealthcare · Medical Devices

LUNG Stock Forecast: Pulmonx Corp. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$2.26
−1.74% on the day

The 5 Wall Street analysts covering Pulmonx Corp. hold a median 12-month price target of $3 — +32.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 74 of 100 as at 22 Aug 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$97.1M
Ticker Nerd rank
74 / 100
Median analyst target
$3.00
Analysts covering
5
Total return, dividends reinvested
1W
−6.6%
1M
+78.0%
YTD
+2.3%
1Y
+47.7%
From 52W high
−13.1%
From 52W low
+93.2%
$1.17
$2.60
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LUNG stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Pulmonx Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
74 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
86
Revisions
85
Accruals
82
Size
76
Issuance
55
Quality
44
Value
38
Momentum
32
Volatility
16

Growth (86): Sales and profits are climbing, and climbing faster than before.

Volatility (16): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LUNG stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LUNG, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00Oct 25Jan 26Apr 26Jul 26LUNGHigh $5.00Median $3.00Low $2.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says5 analysts
3 Buy2 Hold0 Sell
Low $2.50Median $3.00High $5.00

The green dot is the last close — the median target sits +32.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
30 Apr 2026D. Boral CapitalMaintainsBuy—
30 Apr 2026D. Boral CapitalMaintainsBuy$14
5 Mar 2026Canaccord GenuityMaintainsBuy—
5 Mar 2026D. Boral CapitalMaintainsBuy—
20 Feb 2026D. Boral CapitalMaintainsBuy—
13 Nov 2025D. Boral CapitalMaintainsBuy—
28 Oct 2025D. Boral CapitalMaintainsBuy—
28 Oct 2025Lake StreetMaintainsBuy—
8 Sept 2025D. Boral CapitalMaintainsBuy—
1 Aug 2025Wells FargoMaintainsEqual-Weight—
31 July 2025D. Boral CapitalMaintainsBuy—
31 July 2025Lake StreetMaintainsBuy—
31 July 2025Piper SandlerDowngradeNeutral—
31 July 2025StifelMaintainsBuy—
22 May 2025CitigroupMaintainsNeutral—
1 May 2025Canaccord GenuityMaintainsBuy—
1 May 2025D. Boral CapitalMaintainsBuy—
1 May 2025Piper SandlerReiteratesOverweight—
11 Mar 2025D. Boral CapitalMaintainsBuy—
10 Mar 2025D. Boral CapitalInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LUNG appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

LUNG analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
0
Fundamentals

Pulmonx Corp. (LUNG) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.7×

Cheaper than 84% of US stocks

Price / sales
1.1×

Cheaper than 68% of US stocks

Price / book
2.5×

Cheaper than 40% of US stocks

EV / EBITDA
−2.1×

Cheaper than 72% of US stocks

Growth & margins
Revenue growth (YoY)
−4.6%

Higher than 20% of US stocks

Earnings growth (YoY)
—
Gross margin
78.0%

Higher than 89% of US stocks

Operating margin
−39.8%

Higher than 18% of US stocks

Net margin
−55.0%

Higher than 10% of US stocks

Returns & dividend
Return on equity
−88.9%

Higher than 14% of US stocks

Return on assets
−22.1%

Higher than 18% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

LUNG vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
LUNGPulmonx Corp.$97.1M
74
ECORelectroCore, Inc.$94.8M
54
HYPRHyperfine, Inc.$95.7M
56
MBOTMicrobot Medical, Inc.$100.7M
15
LNSRLENSAR, Inc.$103.6M
60
SERASera Prognostics, Inc.$83.8M
40
RPIDRapid Micro Biosystems, Inc.$83.7M
32

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Pulmonx Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LUNG news & analysis

Pulmonx Rebuilds Sales Force, Targets Growth and AeriSeal Launch Next Year

MarketBeat · 15 Aug 2026positive

Pulmonx is rebuilding its sales organization to return to growth, and CEO Glen French said during a Canaccord fireside chat that the company is preparing for potential commercialization of its AeriSeal therapy outside the United States in the second half of next year.

Why it matters — A LUNG watcher would care because the company's sales-force rebuild and planned international AeriSeal commercialization signal near-term strategic moves that could affect revenue and pipeline progress.

What Makes Pulmonx Corporation (LUNG) a Strong Momentum Stock: Buy Now?

Zacks Investment Research · 14 Aug 2026neutral

Zacks Investment Research published an article examining whether Pulmonx Corporation (LUNG) qualifies as a strong momentum stock pick. The piece evaluates the company's characteristics for momentum investors.

Why it matters — The article signals that analysts are assessing LUNG's momentum profile, which could influence investor attention on the stock.

Pulmonx (LUNG) Upgraded to Buy: What Does It Mean for the Stock?

Zacks Investment Research · 3 Aug 2026positive

Zacks Investment Research upgraded Pulmonx (LUNG) to a Zacks Rank #2 (Buy), citing growing optimism about the company's earnings prospects. The report suggests the stock could move higher on this improved outlook.

Why it matters — Pulmonx watchers would care because the Zacks upgrade reflects improved expectations for the company's earnings trajectory, which can influence how investors view the stock.

Pulmonx Corporation (LUNG) Q2 2026 Earnings Call Transcript

Seeking Alpha · 30 July 2026neutral

Pulmonx Corporation held its Q2 2026 earnings conference call, and a transcript of the call has been published by Seeking Alpha.

Why it matters — Earnings call transcripts provide LUNG watchers with detailed insights into the company's quarterly financial performance and management's outlook.

Pulmonx Q2 Earnings Call Highlights

MarketBeat · 29 July 2026positive

Pulmonx reported second-quarter revenue of $22.8 million and reaffirmed its full-year 2026 revenue outlook. Executives also highlighted progress in rebuilding the U.S. sales organization, reducing operating expenses, and preparing to resume China shipments.

Why it matters — LUNG watchers would care because the company's progress on U.S. sales team rebuilding, expense reduction, and potential return to the Chinese market could shape its near-term performance.

FAQ

Frequently asked questions about LUNG stock

What is the LUNG stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Pulmonx Corp. have a median 12-month price target of $3, with estimates ranging from $2.5 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LUNG stock a buy right now?

Of the 5 analysts covering Pulmonx Corp., 3 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Pulmonx Corp. 74 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LUNG?

As at 22 Aug 2026, Pulmonx Corp. ranks 74 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (86 of 100).

Will LUNG stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +32.7% from the last close, and Ticker Nerd's factor model ranks Pulmonx Corp. 74 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LUNG stock forecast for 2030?

No analyst covering Pulmonx Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LUNG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.5 to $5 over the next 12 months.

How has LUNG stock performed over the past year?

Pulmonx Corp. returned +47.7% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Pulmonx Corp. do?

Pulmonx Corporation is a leading medical technology company specializing in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The company focuses on developing and commercializing advanced technologies that offer new options for patients suffering from lung disorders.

What is the latest news on LUNG?

The most recent item we track (MarketBeat, 15 Aug 2026): "Pulmonx Rebuilds Sales Force, Targets Growth and AeriSeal Launch Next Year". Pulmonx is rebuilding its sales organization to return to growth, and CEO Glen French said during a Canaccord fireside chat that the company is preparing for potential commercialization of its AeriSeal therapy outside the United States in the second half of next year.

Company

About Pulmonx Corp.

Pulmonx Corporation is a leading medical technology company specializing in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The company focuses on developing and commercializing advanced technologies that offer new options for patients suffering from lung disorders. One of its flagship products, the Zephyr Valve, is a tiny device designed for bronchoscopic lung volume reduction in severe emphysema patients, providing an alternative to invasive surgical procedures. Pulmonx's innovative solutions impact the healthcare sector by improving patient outcomes and offering healthcare providers effective, less invasive treatment options. By driving advancements in respiratory care, Pulmonx plays a significant role in the growing medical device industry, particularly within the respiratory segment, as the demand for novel therapeutic options for chronic lung diseases increases. Headquartered in Redwood City, California, the company collaborates with medical professionals worldwide to expand access to its life-changing technologies.

CEO Mr. Steven S. Williamson · 7,859 employees · Japan · https://www.nisshin.nipponsteel.com